Vincenzo Volpe

Representative Strategic Company Experience

• Chiesi Farmaceutici in its proposed acquisition of KalVista Pharmaceuticals, Inc., a transaction valued at approximately $1.9 billion.
• Hitachi Rail in its definitive agreement to acquire Clever Devices, an intelligent transportation technology provider.
• Becton Dickinson on its $17.5 billion divestiture to Waters Corporation.
• Lantheus Medical Imaging Inc. in its definitive agreement to acquire Evergreen Theragnostics Inc. in an all-cash transaction consisting of a $250 million upfront payment and up to $752.5 million in potential milestone payments.
• Becton Dickinson on its $4.2 billion acquisition of Edwards Lifesciences’ Critical Care business.
• Legends Hospitality, a sports and entertainment premium experiences company, in its acquisition of ASM Global to create a global live events company.
• ImmunoGen in its $10.1 billion sale to AbbVie.
• Provention Bio, Inc. in its sale to Sanofi for approximately $2.9 billion.
• HUTCHMED in connection with a worldwide licence agreement with Takeda Pharmaceutical for up to $1.13 billion.
• Takeda Pharmaceutical Company Limited on its acquisition of GammaDelta Therapeutics Limited, a company focused on exploiting the unique properties of gamma delta (γδ) T cells for immunotherapy.
• Acceleron Pharma on its approximately $11.5 billion sale to Merck.
• Medtronic in its acquisition of Intersect ENT for approximately $1.1 billion.
• Sunovion Pharmaceuticals, a subsidiary of Japan’s Sumitomo Dainippon Pharma, in a billion-dollar worldwide co-development and co-commercialisation agreement with Otsuka Pharmaceutical Co., Ltd. for four novel neurology drugs.
• Takeda Pharmaceutical Company Limited in an exclusive collaboration and licence agreement with JCR Pharmaceuticals Co., Ltd. to commercialise JR-141 for the treatment of Hunter syndrome.
• Alibaba, on its strategic partnership and joint venture (in conjunction with Richemont) with Farfetch Limited, a NYSE-listed leading global online luxury fashion retailer.
• Asklepios BioPharmaceutical, a U.S. biopharmaceutical company specialising in the development of gene therapies, on its sale to Bayer AG.
• Medtronic in its acquisition of Companion Medical, developer of InPen, a smart insulin pen for the treatment of diabetes.
• Aimbridge Hospitality, North America’s largest independent hotel management firm and a portfolio company of Advent International, on the antitrust aspects of its merger with Interstate Hotels & Resorts.
• Wieland-Werke AG in its $1.2 billion acquisition of Global Brass and Copper Holdings, Inc.
• Medtronic on its $1.64 billion acquisition of Mazor Robotics Ltd.
• Alibaba on the merger control aspects of its strategic partnership with Richemont to bring the retail offerings of YOOX Net-A-Porter Group to Chinese consumers, (“TMT Deal of the Year”).
• Medtronic on the CMA review of its preferred partnership with Animas Corporation.

Representative Private Equity Experience

• Bain Capital in connection with its €955.3 million acquisition of Caverion Corporation.
• CIRCOR International in its take-private sale to global investment firm KKR in a cash transaction valued at approximately $1.6 billion.
• TPG Inc. on the sale of Immucor to Werfen for $2 billion.
• Bain Capital in connection with its $150 million minority investment in Ataccama.
• Baring Private Equity Asia on the European Commission review of its and PAI Partners’ acquisition of World Freight Company International.
• Genstar Capital on the acquisition of Lightspeed Systems, the market leader in online student safety and effectiveness.
• CVC Capital Partners and its portfolio company System C on the acquisitions of Clevermed and Oxford Computer Consultants.
• Inflexion, a UK-headquartered private equity firm, on the sale of Reed & Mackay, a premium corporate travel management and events business, to TripActions, a U.S.-headquartered business travel and spend management platform.
• TPG Inc. on the sale of McAfee Corp’s Consumer business to an investor group for over $14 billion.
• TPG Inc. on the sale of McAfee Corp’s Enterprise business to a consortium led by Symphony Technology Group for $4 billion.
• Avista Capital Partners on its sale of Acino, a Swiss pharmaceutical company, to ADQ, a sovereign wealth fund located in Abu Dhabi.
• Bain Capital in connection with its investment in EnterpriseDB.
• Cove Hill Partners on its $500 million sale of LiveAuctioneers to Auction Technology Group.
• Advent International Corp. in its acquisition of Nielsen’s Global Connect business for $2.7 billion.
• Avista Capital Partners on its joint acquisition with VHC Investco of Vision Healthcare, one of Europe’s fastest-growing omni-channel and direct-to-consumer health care companies.
• Charlesbank Capital Partners in the acquisition by its portfolio company Sound United LLC of Bowers & Wilkins, a leading designer and manufacturer of luxury audio products.
• Charlesbank Capital Partners in its investment in Park Place Technologies, a leading global third-party maintenance provider, alongside GTCR.
• Avista Capital Partners on the antitrust aspects of the sale of Trimb Healthcare to Karo Pharma, cleared subject to divestitures.
• Genstar Capital on the merger control review of its acquisition of certain assets of Amcor Flexibles.

Representative Secondaries Transactions Experience

• Regularly advises an Asian sovereign investor on their primary, co-investment and secondaries programs

Notable transactions in which Vincenzo has been involved prior to joining the firm include:

• Liberty Media Corporation in national merger control approvals of its acquisition of Formula One
• Halliburton in seeking to receive EU merger control approval of its $28 billion proposed acquisition of Baker Hughes
• Dresser-Rand in EU and other merger control approvals of its $7.8 billion merger with Siemens
• a leading electronic commerce and cloud computing company on the compliance of its business strategy with EU competition law
• a major airline in the context of state aid litigation before the General Court of the EU